Targeting therapy-persistent residual disease.
Nat Cancer
; 5(9): 1298-1304, 2024 Sep.
Article
en En
| MEDLINE
| ID: mdl-39289594
ABSTRACT
Disease relapse driven by acquired drug resistance limits the effectiveness of most systemic anti-cancer agents. Targeting persistent cancer cells in residual disease before relapse has emerged as a potential strategy for enhancing the efficacy and the durability of current therapies. However, barriers remain to implementing persister-directed approaches in the clinic. This Perspective discusses current preclinical and clinical complexities and outlines key steps toward the development of clinical strategies that target therapy-persistent residual disease.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasia Residual
/
Neoplasias
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Nat Cancer
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos